Eli Lilly and Company (NYSE: LLY) is one of the world’s largest pharmaceutical companies, with a market capitalisation approaching $846 billion driven by extraordinary demand for its GLP-1 drugs Mounjaro and Zepbound. For Muslim investors asking “is Eli Lilly ethical-trading/” style=”color:#D8AF44;text-decoration:underline” title=”Ethical Trading”>halal?”, the answer is unfortunately negative — not because of what Lilly does, but how it finances its operations.
What We Screen For
Shariah-compliant equity screening examines three core financial ratios:
- Debt Purity — Measures interest-bearing debt relative to market capitalisation. Higher scores indicate lower debt dependency.
- Liquidity Purity — Assesses whether a company’s assets are predominantly productive. Scores above 50% are preferred.
- Revenue Purity — Evaluates what share of revenue derives from permissible activities. Scores above 67% indicate compliance.
The Numbers
| Screening Ratio | Eli Lilly Score | Threshold | Status |
|---|---|---|---|
| Debt Purity | 0.00% | >50% | ✗ Fail |
| Liquidity Purity | 98.20% | >50% | ✓ Pass |
| Revenue Purity | 100.00% | >67% | ✓ Pass |
| Overall Ethical Score | 58.29% | — | Silver Tier |
Detailed Assessment
Eli Lilly is a frustrating case for Shariah-conscious investors because the company’s core business is as clean as it gets. Revenue purity is a perfect 100% — every dollar of Lilly’s income comes from pharmaceutical product sales. Developing medicines for diabetes, obesity, Alzheimer’s, and cancer is universally regarded as beneficial and permissible.
Liquidity purity at 98.20% is equally strong. Lilly’s asset base is dominated by manufacturing facilities, R&D infrastructure, and intellectual property — productive assets that serve society.
The problem is debt. Debt purity scores 0.00%, a complete failure. Lilly has taken on substantial interest-bearing debt to fund its aggressive expansion of manufacturing capacity for GLP-1 drugs. The company’s long-term debt exceeds $30 billion, and it has relied heavily on bond markets to finance new plants in Indiana, Ireland, and Germany. While the spending is directed toward life-improving products, the financing mechanism is interest-based.
This creates an uncomfortable paradox: a company doing some of the most beneficial work in healthcare, funded through impermissible means. The 58.29% overall score and Silver Tier classification reflect excellent operational compliance undermined by financial structure.
Shariah-Compliant Alternatives in Healthcare
For halal pharmaceutical exposure with better debt profiles:
- Johnson & Johnson (JNJ) — Diversified healthcare with a historically conservative balance sheet.
- Procter & Gamble (PG) — Consumer health and hygiene products, lower leverage profile.
Explore the full list on our Ethical Trading Screener.
Further Research
View the full Eli Lilly profile on our LLY Ticker Page.
Explore Shariah-screened equities on our Ethical Trading Screener.
Deepen Your Understanding
Related articles from the Titan Protect Foundry: